The Latest Breaking News from Eli Lilly

This trend drove WeGovy sales to jump 27 times higher — a 2,660% increase — on Wednesday compared with the typical daily average last month.

Although the market has been uncomfortably choppy in recent sessions, this is also the time for contrarians to pick up hot securities on the cheap.

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.